

This is a repository copy of *A dynamic, modifiable model for estimating cost-effectiveness of smoking cessation interventions in pregnancy : application to an RCT of self-help delivered by text message*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/138623/>

Version: Published Version

---

## Article:

Jones, Matthew, Smith, Murray, Lewis, Sarah et al. (2 more authors) (2019) A dynamic, modifiable model for estimating cost-effectiveness of smoking cessation interventions in pregnancy : application to an RCT of self-help delivered by text message. *Addiction*. pp. 353-365. ISSN 1360-0443

<https://doi.org/10.1111/add.14476>

---

## Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new works must also acknowledge the authors and be non-commercial. You don't have to license any derivative works on the same terms. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

## Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.

# A dynamic, modifiable model for estimating cost-effectiveness of smoking cessation interventions in pregnancy: application to an RCT of self-help delivered by text message

Matthew Jones<sup>1</sup> , Murray Smith<sup>2</sup>, Sarah Lewis<sup>3</sup>, Steve Parrott<sup>4</sup> & Tim Coleman<sup>1</sup> 

Division of Primary Care, University of Nottingham, Nottingham, UK,<sup>1</sup> Community and Health Research Unit, University of Lincoln, Lincolnshire UK,<sup>2</sup> Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK<sup>3</sup> and Department of Health Sciences, University of York, York, UK<sup>4</sup>

## ABSTRACT

**Background and Aims** Previous evaluations of smoking cessation interventions in pregnancy have several limitations. Our solution to these limitations is the Economics of Smoking in Pregnancy (ESIP) model, which estimates the life-time cost-effectiveness of smoking cessation interventions in pregnancy from a National Health Service (NHS) and personal social services perspective. We aim to (1) describe how ESIP has been constructed and (2) illustrate its use with trial data. **Methods** ESIP links mothers' and offspring pregnancy outcomes to estimate the burdens of smoking-related disease they experience with different rates of smoking in pregnancy, both in pregnancy and throughout their life-times. Smoking rates are inputted by model users. ESIP then estimates the costs of treating disease burdens and also mothers' and offspring life-years and quality-adjusted life years (QALYs). By comparing costs incurred and healthy life following different smoking rates, ESIP estimates incremental cost-effectiveness and benefit-cost ratios for mothers or offspring or both combined. We illustrate ESIP use using data from a pragmatic randomized controlled trial that tested a smoking cessation intervention in pregnancy. **Results** Throughout women's and offspring life-times, the intervention proved cheaper than usual care, having a negative incremental cost of £38.37 (interquartile range = £21.46–56.96) and it improved health, demonstrating a 0.04 increase in incremental QALYs for mothers and offspring, implying that it is 'dominant' over usual care. Benefit-cost ratios suggested that every £1 spent would generate a median of £14 (interquartile range = £8–20) in health-care savings. **Conclusions** Economics of Smoking in Pregnancy is the first economic model to link mothers' and infants' costs and benefits while reporting cost-effectiveness in readily-comparable units. Using ESIP with data from a trial which reported only short-term economic analysis showed that the intervention was very likely to be cost-effective in the longer term and to generate health-care savings.

**Keywords** Cost-effective, economic evaluation, pregnancy, smoking, smoking cessation, tobacco.

Correspondence to: Matthew Jones, Division of Primary Care, Room 1403, 14th Floor Tower Building, University Park, University of Nottingham, Nottingham NG7 2RD, UK. E-mail: matthew.jones3@nottingham.ac.uk

Submitted 30 May 2018; initial review completed 10 August 2018; final version accepted 16 October 2018

## INTRODUCTION

Tobacco smoking during pregnancy remains a major global public health concern estimated to cost £23.5 million annually in the United Kingdom [1] and US\$110 million in the United States; [2] the prevalence varies from 39% in Spain [3] to 23% in Canada [4] and 12–14% in the United Kingdom, United States, Australia and Germany [5–8]. Many mothers expose themselves and

their offspring to both pregnancy-related and long-term risks from smoking [9–12].

Economic evaluation is important for demonstrating the value for money afforded by programmes competing for scarce health-care resources. Previous evaluations of smoking cessation interventions for pregnant women have been inconsistent, making comparison of findings difficult [13]. For example, models have: treated maternal and infant health outcomes as mutually exclusive [14]; provided

outputs in 'cost-per-quitter' units which cannot be compared with other economic measures [15]; not adequately justified the inclusion of morbidities [16]; or have provided only limited allowance for uncertainty [17].

We describe the Economics of Smoking in Pregnancy (ESIP) model which we designed to address these limitations, by estimating the future health gains and treatment costs associated with both the mother and her infant up to the age of 100 years, using a UK National Health Service (NHS) and Personal Social Services (PSS) perspective [18]. We also demonstrate how ESIP estimates the cost-effectiveness of a within-pregnancy cessation intervention by using the data from a recently published trial.

## DESCRIPTION OF ESIP MODEL

### Overview


The cost-effectiveness of a smoking cessation intervention can be expressed as the ratio of the increased 'per-person' costs of providing that intervention to the 'per-person' health benefits that the intervention causes. In the short term, costs mainly comprise paying for intervention delivery; however, if an intervention promotes cessation and smoking-related diseases occur less frequently, then longer-term costs for treating these reduce. For women and infants and for different smoking rates in pregnancy, ESIP estimates the burden of smoking-related disease in pregnancy and during their life-times and calculates the health service costs incurred treating this. ESIP also estimates the potential life years that women and infants can expect before adjusting these into standard economic

terminology, quality-adjusted life years (QALYs). By comparing costs incurred due to different smoking rates, ESIP estimates how much an intervention costs or saves; similarly, by comparing healthy life which accrues following different smoking rates in pregnancy, ESIP estimates whether a cessation intervention provides health benefit; finally, these cost and benefit estimates are combined to generate cost-effectiveness measures.


### ESIP components

Figure 1 provides a simplified maternal model structure (full detail in Supporting information, Appendix S1). A hypothetical cohort of 1000 singleton-pregnancy women who smoke enter a decision tree (left-hand side), which estimates smoking-related morbidity in pregnancy; the first branch of this tree is where smoking rates in pregnancy are entered into the model, affecting all model calculations. The tree determines women's smoking behaviour at childbirth, whether or not they survive pregnancy and whether live births occur. Next, surviving women enter a 'life-time' Markov chain model component (right-hand side) that predicts changes in their life-time smoking behaviour and, dependent on this, determines their life-time burden of smoking-related morbidity and mortality. We defined 'life-time' as modelling women's and infants' outcomes until 100 years old or death.

Figure 2 shows a simplified fetal model structure (Supporting information, Appendix S1). Fetuses conceived by virtual cohort women enter a decision tree (left-hand side) which determines how many survive to birth and, of these, what proportion have low birth weights. Key



**Figure 1** Simplified maternal model: women progress through 'within-pregnancy' decision tree determining their 'states' on entry to life-time Markov component



**Figure 2** Simplified fetal and infant model: offspring progress through ‘within-pregnancy’ decision tree determining ‘states’ for entry into Markov childhood and life-time components

parameters in the fetal decision tree (e.g. proportion of stillbirths) are generated in the maternal one; hence, both are linked and fetal pregnancy and birth outcomes are dependent on smoking rates entered into the maternal tree. Between birth and 15 years infants enter a ‘childhood’ Markov chain component (middle section) which estimates their burden of asthma, factoring in the impact of second-hand exposure to maternal smoking, with smoking rates used, coming from the maternal life-time model. However, not all women who smoke expose their child to their smoking, and this is allowed for (see Table S1 in Supporting information, Appendix S2). However, it is assumed that once a mother exposes a child to passive smoking, this behaviour would not change. This component also estimates children’s rates of smoking uptake incorporating an allowance for the influence of maternal smoking [19]. Finally, at 16 years children enter an ‘adulthood’ Markov chain component (right-hand side) which estimates their life-time burden of smoking-related morbidities and mortality.

### Inclusion of morbidities

We want decision trees and Markov components to include only those morbidities which are both caused by smoking and are sufficiently prevalent to have meaningful economic impacts. A scoping review identified smoking-attributable morbidities occurring in pregnancy and in infants [20]. Using the criteria outlined above, decision trees include the following maternal morbidities: placental abruption, ectopic pregnancy, pre-eclampsia, placenta previa and miscarriage (fetal death and expulsion from uterus before 24 weeks). Trees also include the following infant morbidities: low infant birth weight (LBW; i.e. < 2500 g), stillbirth (i.e. born dead after

22 weeks gestation) and premature birth (i.e. born before 37 weeks). For infants in the ‘childhood’ component, we included asthma [21,22]. For both women’s and infants’ ‘life-time’ components, as in other models [17,23,24], we included coronary heart disease (CHD) [25], chronic obstructive pulmonary disease (COPD) [26], lung cancer [26] and stroke [27].

### Incorporating maternal smoking behaviour

ESIP incorporates maternal smoking-related data in four places:

- In pregnancy—user input:* as above, the proportions of women anticipated to stop smoking in pregnancy both with and without an intervention are inputted and used at the first node in the maternal decision tree (Fig. 1).
- Maternal ‘life-time’ component:* in the first two postpartum years, relapse to smoking rates are higher than those generally. For women who were not smoking at childbirth a systematic review indicated their probabilities of returning to smoking within the first and second postpartum years (see Supporting information, Appendix S2) [20,28]. For women who smoked at childbirth, we estimated the percentage who would make a quit attempt in the first postpartum year from the 2010 Infant Feeding Survey (IFS), using data reported at 10 months after childbirth as a proxy for 1-year data [29].
- Both ‘life-time’ components:* except for the situation in (ii) above, we used English ONS smoking data to annually estimate ‘transition probabilities’, the annual probabilities of moving between smoking ‘states’ (see Supporting information, Appendix S2 and section C1 in Appendix S3) [22]. To estimate the annual probability of restarting smoking after long abstinence periods,

we used 8-year follow-up data from a smoking cessation trial (see Supporting information, Appendix S2 and section C2 in Appendix S3) [30].

- iv) 'Childhood' component: we used Health Survey for England data to estimate the proportion of maternal smokers who exposed children to passive smoking [31], and systematic review findings [19] were used to calculate teenagers' probabilities of starting smoking, given that their mothers smoked (see section C2 in Supporting information, Appendix S3).

### Determining smoking-related morbidity

To estimate accurately the burden of smoking-related morbidity, ESIP needed contemporary data on the frequency with which included conditions occurred. For nodes in decision tree components, we sought proportions of women and fetuses developing smoking-related morbidities. We sourced data on frequency of fetal loss, maternal morbidities and gestational length from Hospital Episode Statistics (HES) NHS Maternity Statistics for England (2006–16) [32] on gestation-specific infant mortality from Office of National Statistics (ONS), England and Wales (2006–12) [33] and on live births and stillbirths by birth weight and prematurity from Child Mortality Statistics (2006–12) [34]. A technical explanation of how the proportions were calculated can be found in section C3 in Supporting information, Appendix S3. To estimate the probabilities that 'never smokers' or their fetuses might experience morbidities, we adjusted bootstrapped proportions, using the same approach. Odds ratios and relative risks representing the increased harm caused by smoking during pregnancy came from three systematic reviews [9–11]. Probability estimates can be found in Supporting information, Appendix S2.

For life-time, childhood and adulthood components, we calculated the number of women/infants with smoking-related morbidities using English age- and gender-specific prevalence for asthma, CHD, COPD, lung cancer and stroke [35–37]; relative risks for current and former smokers experiencing these were sourced from a US Surgeon General's report (see section C4 in Supporting information, Appendix S3) [38]. Where the model predicted that a cohort member had been abstinent for more than 1 year, they were treated as former smokers. For the 'childhood' component, we adjusted asthma prevalence for low birth weight and passive smoking exposure, as both may increase asthma risk (see section C5 in Supporting information, Appendix S3) [20–22,39,40]. Odds ratios for developing asthma after low birth weight birth and following exposure to maternal smoking in pregnancy and passive smoking came from the literature [40,41].

Prevalence estimates used are shown in Supporting information, Appendix S4.

### Determining smoking-related mortality

To estimate maternal deaths in pregnancy in ESIP, we used ONS mortality statistics (2006–15) to apply morbidity-specific probabilities of death with no adjustment for smoking behaviour, as there was no evidence that this influenced chances of dying from within-pregnancy morbidities (see section C6 in Supporting information, Appendix S3) [42,43]. For the 'life-time' and offspring 'adulthood' components, we estimated male and female mortality using ONS cohort life tables [44]. Probabilities were adjusted using relative risks from Doll *et al.* to represent the impacts on mortality of smoking and former smoking (see Supporting information, Appendix S4 and section C7 in Appendix S3) [26,45], with prevalence for current-, former- and never-smoking taken from ONS data [46]. When allocating mortality probabilities, those abstinent for more than 1 year were treated as former smokers. For the 'childhood' component, we similarly adjusted mortality rates to allow for the impact of LBW, using odds ratios for LBW-specific mortality (see section C8 in Supporting information, Appendix S3) [47].

### Determining health-related quality of life

ESIP calculates the potential for healthy life experience by first awarding 'life years' to women and offspring, with the numbers of years lived by cohort members being determined by model components. Life years are then converted into QALYs. We assigned life years to mothers at the end of pregnancy, adjusting for gestational length by assuming that a pregnancy lasts 40 weeks. Informed by HES NHS Maternity Statistics for England, we assumed the average gestational length after ectopic pregnancy was 10 weeks, miscarriage (14 weeks), premature birth (33 weeks), placenta previa (38 weeks) and abruption and pre-eclampsia (39 weeks) [32]. After birth, we first awarded 1 life year to offspring for each year of life.

To generate QALY estimates, life years were weighted by previously estimated utility tariffs [48]. We found no evidence to suggest that there was any maternal quality of life loss associated with pre-eclampsia, and assumed the same for placental abruption and placenta previa [20,49]. A one-off 0.1 utility loss was applied to all women who experienced a fetal loss (ectopic pregnancy, miscarriage and stillbirth) [50], and was applied in the within-pregnancy decision tree. For ectopic pregnancy there was an additional one-off utility loss of 0.01 applied in the within-pregnancy decision trees [51]. Utility weights for smoking-related morbidities were applied to mothers and offspring aged 16 and above were 0.73 [standard error



(SE = 0.3)] for CHD [52], 0.73 (SE = 0.23) for COPD [53], 0.67 (SE = 0.22) for lung cancer [54] and 0.72 (SE = 0.32) for stroke [55]. In the 'childhood' component the utility value for offspring aged 1–15 years in perfect health was 1 and, for children with asthma, 0.9 (SE = 0.18) [56].

### Estimating health-care costs

ESIP's determination of health-care costs depends on the burden of morbidity estimated. Health-care events experienced by both mothers and fetuses were counted only once, hence costs were split between maternal and infant components to avoid duplication. Costs attributed only within the maternal components were those of antenatal care, treatment(s) for within-pregnancy morbidities, stillbirth and mode of delivery. Neonatal care costs for infants born with LBW and prematurity and treatment costs for childhood asthma were attributed only in infant components. Treatment costs associated for 'life-time' morbidities were attributed in both maternal and infant components. ICD-10 codes were linked to Healthcare Resource Groups (HRG) currency codes, and hence to NHS reference costs (see Supporting information, Appendix S5) [57]. Treatment costs for morbidities and delivery were then calculated across the different health-care settings to estimate a weighted mean [58]. The cost of a cardiac event was used as a proxy for the cost of a maternal death [1]. A practising NHS midwife advised on attribution of health-care costs and a detailed explanation of these is shown in Supporting information, Appendix S5. All pregnancies received an antenatal care cost amended for gestational length, morbidity and, for live births, a delivery cost. All live-born infants received a neonatal care cost based upon length of gestation, using weighted neonatal care costs by the average gestation-adjusted length of stay in a neonatal intensive care unit [59]. Treatment costs for 'life-time' morbidities and childhood asthma were taken from the literature [60–62], and inflated to 2014–15 prices [63]. Individual cost components are shown in Table 1.

### Incorporating uncertainty

To enable ESIP outputs to reflect the uncertainty of estimates, we fitted distributions enabling probabilistic sensitivity analysis (PSA) using established methods [64]. ESIP has 390 variables with fitted distributions and performs 10 000 Monte Carlo simulations to control for uncertainty [65]. A technical description can be found in section C9 in Supporting information, Appendix S3.

### Analysis and outcomes

ESIP is constructed in Microsoft Excel 2010 [66] and is available online at [https://www.nottingham.ac.uk/research/groups/tobaccoandalcohol/smoking-in-](https://www.nottingham.ac.uk/research/groups/tobaccoandalcohol/smoking-in-pregnancy/esip/index.aspx)

**Table 1** Cost components for 'within-pregnancy', 'life-time', 'childhood' and 'adulthood' maternal and infant components.

Input	Mean (£)	SE (£)
Within-pregnancy maternal morbidity treatment		
Ectopic and miscarriage	578.07	226.31
Abruption and previa	1202.38	559.71
Pre-eclampsia	657.89	329.60
Obstetrician first visit	146.38	68.31
Obstetrician subsequent visit	113.90	62.86
Routine observation after birth	345.24	206.71
Death	1630.98	854.11
Within-pregnancy maternal birth		
Normal birth	2497.05	745.03
Emergency caesarean section	4180.54	1214.01
Caesarean section	3781.28	1072.94
Stillbirth	1063.28	676.26
Within-pregnancy maternal ante-natal care		
Community midwife visit	55.51	17.29
Standard ultrasound scan	110.77	60.65
Specialized ultrasound scan	131.81	50.98
Within-pregnancy infant delivery		
Neonatal care (premature)	15 934.55	7127.79
Neonatal care (full gestation)	2645.87	2423.44
Childhood treatment		
Asthma	1624.00	162.40
Life-time morbidity treatment		
CHD	1838.62	183.86
COPD	843.65	84.37
Lung cancer	9554.98	955.50
Stroke	4347.08	29.59

SE = standard error; CHD = coronary heart disease; COPD = chronic obstructive pulmonary disease.

pregnancy/esip/index.aspx. Because we adopted a UK NHS and PSS perspective [18], costs and benefits accrued after pregnancy (i.e. in life-time components) were discounted at 3.5% [18]. Markov chains are run in annual cycles up to age 100.

The key outcomes ESIP produces are incremental cost-effectiveness ratios (ICERs) per additional QALY for mother and child, presented both separately and as a combined 'per pregnancy' measure of cost-effectiveness with a 'life-time' perspective. Other outcomes are ICERs per additional life year and per additional quitter, and all outcomes can also be reported to reflect cost-effectiveness measured only until the end of pregnancy.

Return on investment (ROI) estimates can also be produced for maternal and infant health care, both separately and combined, and reported for all time horizons. These are benefit–cost ratios, defined as incremental health-care savings divided by incremental intervention cost.

ESIP can also estimate the following ICERs at end of pregnancy: per experience of maternal morbidity, infant death (fetal loss and stillbirth), premature birth, LBW birth and per adverse birth outcomes avoided. Output from the

PSA is demonstrated by incremental cost-effectiveness plane scatterplots and cost-effectiveness acceptability curves (CEACs), which illustrate the likelihood that an intervention might be judged to be cost-effective at preselected thresholds.

## USING ESIP WITH TRIAL DATA: A WORKED EXAMPLE

In this section we demonstrate the use of published data from the 'MiQuit' pilot randomized controlled trial (RCT) in conjunction with the ESIP model to estimate the cost-effectiveness of the intervention used: self-help smoking cessation support delivered by text message [67,68]. Participants were pregnant smokers who received standard NHS smoking cessation care with an intervention group additionally receiving a 12-week programme of tailored text messages; for full details see Naughton *et al.* [68]. No pregnancy outcome data were collected, follow-up ended at 36 weeks gestation and a simple economic evaluation estimated a 'cost per quitter' of £134 [95% confidence interval (CI) = -£396 to £844], basing this only upon intervention costs incurred during pregnancy [68].

### Inputting data

The following data from the trial paper are inputted (values in brackets): mean maternal age (27 years); birth year (2014); per-participant intervention cost (£3.04, standard error = £0.30) and control and intervention group quit rates (2 and 5.4%). ESIP requires standard errors for cessation outcome data; as these were not reported [67,68] they were estimated as 1.6 and 1.1%, respectively, using established methods [69,70]. As MiQuit was delivered in addition to standard NHS treatment, we assumed that, in the worst-case scenario, MiQuit would not improve the chances of a woman quitting over NHS treatment. Therefore, we restricted ESIP to not sample MiQuit quit rates below that of NHS treatment; where this did happen (i.e. sampled MiQuit quit rate was less than sampled NHS treatment), ESIP would assume that the quit rates in the intervention and comparison were equivalent.

### ESIP outputs

Although the published trial economic analysis suggested that the MiQuit intervention was potentially cost-effective, as measured in 'cost-per-quitter' units [68], ESIP shows that the greatest health benefits come in the longer term and it also estimates value for money in terms of QALYs, life years and in ROI, none of which was possible in the original trial.

More specifically, Table 2 shows base case (using initial model input values with no allowance for uncertainty) and

PSA (allows model inputs to vary to estimate the impact of uncertainty) findings. The base case suggests that MiQuit is dominant because it is more effective and cheaper than standard NHS care (incremental cost was negative). The benefit-cost ratio suggests that for every £1 spent on MiQuit the health-care provider could expect to save £14 per pregnancy throughout the life-time of the mother and offspring, a finding reinforced by PSA, which demonstrates negative median incremental costs and positive median incremental life years/QALYs with an interquartile range suggesting that the saving could be as little as £8 and as great as £20. The scatterplot of incremental costs versus incremental QALYs (see left-hand side of Fig. 3) demonstrates that the majority of iterations can be found in the south-east quadrant (i.e. indicating cost-effectiveness) [71], and the associated cost-effectiveness acceptability curve (CEAC) (right-hand side of Fig. 3) suggests that MiQuit has a probability 0.95 of being cost-saving, which increases to 0.97 when a decision-maker is willing to pay £20 000 to gain an additional QALY.

Table 3 provides results constrained to the end-of-pregnancy time horizon, including estimates for infant morbidities averted by using the intervention. Although ESIP estimates that MiQuit increases maternal QALYs and decreases several adverse infant birth outcomes, it is no longer dominant because it also leads to an increase in cost. However, both base case and PSA ICERs are still below commonly accepted threshold values for QALYs so, even in this analysis, MiQuit appears cost-effective against standard care as judged by usual norms [72,73]. Benefit-cost ratios suggested that there may be health-care savings in terms of infant health care; however, this was outweighed by the increased cost associated with the mother.

## DISCUSSION

ESIP is the first economic model to acknowledge that maternal smoking in pregnancy and afterwards directly affects fetal and infant pregnancy outcomes, offspring smoking uptake and life-time experience of smoking-related illness for both mothers and children. Previous models have considered mothers or infants in isolation [14,16,74,75], and none have incorporated the impact of infants' exposures to passive smoking. ESIP estimates not only common measures of cost-effectiveness [13], but also ROI, which may be of interest to decision-makers.

### Impact of modelling assumptions


By assuming that women who stop smoking in pregnancy have the same risks as those who have never smoked, the model may overestimate the benefits and cost-effectiveness of cessation in pregnancy. It is probable that 'quitters' in

**Table 2** ESIP MiQuit trial outputs for women and offspring: base case and probabilistic sensitivity analyses, life-time horizon.

Outcome	Base case (deterministic: no allowance for uncertainty)			Estimates from the probabilistic sensitivity analysis (incorporates uncertainty for model inputs)								
				Comparator		Experimental		Incremental				
	Comparator	Experimental	Incremental	Median	Interquartile range	Median	Interquartile range	Median	Interquartile range			
Maternal outcomes												
Quit rate at delivery (%)	0.0196	0.0542	0.0346	0.0180	0.0119	0.0256	0.0529	0.0431	0.0646	0.0340	0.0214	0.0468
Expected life years per mother	25.1797	25.1827	0.0030	25.2003	25.1634	25.2340	25.2033	25.1670	25.2365	0.0028	0.0018	0.0041
Expected QALYs per mother	23.1165	23.1246	0.0081	23.1946	22.7342	23.5788	23.2028	22.7449	23.5866	0.0074	0.0045	0.0112
Expected cost per mother (£)	10 002.04	9988.28	−13.76	10 033.81	9523.45	10 601.76	10 019.46	9509.49	10 587.53	−13.44	−20.29	−6.99
ICER per additional life year (£)			−4636.23							−4423.80	−5437.41	−3448.47
ICER per additional QALY (£)			−1701.05							−1619.91	−2084.53	−1229.48
ICER per additional quitter (£)			−397.70							−384.84	−461.88	−298.00
Offspring outcomes												
Expected life years per infant	24.0721	24.1020	0.0299	24.0787	23.9804	24.1722	24.1082	24.0143	24.1991	0.0291	0.0181	0.0410
Expected QALYs per infant	23.5449	23.5771	0.0322	23.5953	23.3523	23.7965	23.6282	23.3859	23.8282	0.0310	0.0194	0.0441
Expected cost per infant (£)	7805.18	7777.79	−27.39	7337.74	6409.01	8772.84	7310.38	6380.97	8750.28	−26.37	−39.39	−14.87
ICER per additional life year (£)			−915.58							−884.29	−1104.35	−679.31
ICER per additional QALY (£)			−850.36							−823.64	−1033.68	−625.10
Combined per pregnancy outcomes (mother and offspring)												
Expected life years per pregnancy	49.2519	49.2847	0.0329	49.2754	49.1683	49.3811	49.3091	49.2058	49.4090	0.0321	0.0200	0.0450
Expected QALYs per pregnancy	46.6614	46.7017	0.0403	46.7560	46.1134	47.3147	46.7935	46.1575	47.3575	0.0391	0.0245	0.0552
Expected cost per pregnancy (£)	20 915.76	20 876.48	−39.28	20 677.53	19 251.01	22 428.84	20 638.17	19 212.41	22 383.83	−38.37	−56.96	−21.46
ICER per additional life year (£)			−1194.68							−1150.13	−1422.75	−894.08
ICER per additional QALY (£)			−974.83							−939.53	−1156.12	−737.99
ICER per additional quitter (£)			−1135.27							−1114.32	−1297.95	−909.49
Cost-offset analysis												
Cost savings ratio for maternal health-care only (£)			5.53							5.42	3.30	7.78
Cost savings ratio for offspring health-care only (£)			10.01							9.67	5.84	14.12
Cost savings ratio for combined health-care only (£)			13.92							13.65	8.02	19.98

ESIP = Economics of Smoking in Pregnancy; QALY = quality-adjusted life year; ICER = incremental cost-effectiveness ratio.





**Figure 3** Life-time horizon probabilistic sensitivity analysis: maternal and offspring costs and outcomes with scatterplot and cost-effectiveness acceptability curve

pregnancy will have slightly greater risks of experiencing morbidities than ‘never smokers’, as they will have smoked for at least at some of their pregnancies. However, the increase in risk may be small because, for example, when women quit early in pregnancy their infants’ birth weights are no different from those born to non-smokers [76] and low birth weight is arguably the principal cause of morbidity and mortality among neonates and infants [40,47]. Furthermore, most smokers who stop when pregnant do so early on in pregnancy [77,78], so this assumption may not affect ESIP outputs greatly.

The model assumes that smoking by household members other than mothers have no impact on either children’s passive smoking or their uptake of smoking, so it may underestimate children’s smoking-related morbidity and smoking uptake. If a household has a father or other family members who smoke [19] this has an additional influence on children’s smoking uptake, so the benefits attributable to maternal smoking cessation may be overestimated. However, it has been shown that maternal smoking has more impact on children’s smoking uptake than paternal smoking [19,39], so ESIP incorporates the major influence.

The assumption that smoking mothers do not change their smoking behaviour around their child (i.e. either exposing or not exposing them to second-hand smoking) may mean that ESIP does not estimate children’s smoking-related morbidity accurately. It is unlikely that a mother’s smoking behaviour around her child would remain fixed throughout childhood [79], but we could identify no longitudinal data to inform the model about this, and this remains a model limitation. However, the model does attempt to model maternal smoking behaviour after pregnancy accurately, making use of the most recent data on postnatal relapse, and it could be argued that this will have a more substantial impact.

ESIP allows women to make quit attempts after pregnancy, but because Markov models are ‘memoryless’ it assumes each attempt is independent of previous ones [80].

However, the more quit attempts an individual makes, the more likely that they are to quit successfully [81–84], and a woman takes, on average, 6.3 quit attempts throughout her life-time to become a former smoker [85]. ESIP may, therefore, underestimate long-term abstinence. However, we believe the model makes optimal use of the best available smoking behaviour data and improves on other models by taking into account the different rates of restarting smoking during the first two postnatal years [17,24].

As incorporating subsequent pregnancies would have been challenging, the model assumes that women have only one pregnancy in their life-times. The impact this might have on model estimates is uncertain; ESIP may underestimate health-care costs incurred, but equally it may underestimate siblings’ benefits resulting from mothers’ cessations. In England and Wales in 2013 there was an average of two children in families [86], suggesting that this is a potentially serious limitation. However, if a cessation intervention proved to be cost-effective for a single child, it seems likely that this would also have benefits for any other children (e.g. in reduced passive smoking) and ESIP estimates would be conservative.

The assumption that MiQuit is superior to standard care removes the possibility of negative incremental quit rates between MiQuit and standard NHS care. The MiQuit pilot study found that there was a non-significant increase in abstinence [odds ratio (OR) = 2.7, 95% CI = 0.93–9.35] [68], therefore there is the possibility that MiQuit could decrease the likelihood that a woman quits. By not estimating negative incremental quit rates, ESIP could be overestimating the cost-effectiveness of MiQuit because ESIP is ignoring cases where women and infants are made worse off. However, if MiQuit was to become part of NHS practice in the United Kingdom, it would be delivered in addition to usual care, and hence we considered it additive to usual care rather than replacing it. Furthermore, out of 10 000 replications, this assumption was only applied 345 times, therefore the chance that MiQuit will make

**Table 3** ESIP MiQuit trial outputs for women and offspring: base case and probabilistic sensitivity analyses, end-of-pregnancy horizon.

Outcome	Base case (deterministic: no allowance for uncertainty)			Estimates from the probabilistic sensitivity analysis (incorporates uncertainty for model inputs)								
				Comparator			Experimental			Incremental		
	Comparator	Experimental	Incremental	Median	Interquartile range		Median	Interquartile range		Median	Interquartile range	
Maternal outcomes												
Number of pregnancies with a morbidity	122	121	−1	122	118	126	121	118	125	−1	−1	0
Expected QALYs per mother	0.6842	0.6852	0.0010	0.6841	0.6779	0.6902	0.6852	0.6790	0.6912	0.0010	0.0006	0.0014
Expected costs per mother (£)	3108.55	3113.45	4.91	3046.26	2618.44	3514.32	3050.83	2622.09	3519.06	4.55	3.72	5.72
ICER per morbidity avoided (£)			6093.90							6385.64	4776.11	9152.32
ICER per additional QALY (£)			4930.28							5251.48	3899.71	7414.55
ICER per additional quitter (£)			141.79							149.78	112.89	206.82
Offspring outcomes												
Number of fetal losses (including stillbirths)	106	105	−1	106	103	110	105	102	109	−1	−1	−1
Number of premature births	73	73	0	73	72	74	73	71	74	0	−1	0
Number of LBW infants	113	111	−2	113	111	115	111	109	113	−2	−3	−1
Total number of infants with adverse birth outcomes	213	211	−2	213	210	217	211	208	215	−2	−3	−1
Expected cost per infant (£)	3261.81	3263.58	1.77	2738.18	1821.11	4154.83	2740.49	1820.83	4156.79	1.94	−0.57	3.66
ICER per adverse birth outcome avoided (£)			892.80							1144.95	−258.57	2973.27
Combined per pregnancy outcomes (mother and offspring)												
Expected cost per pregnancy (mother and infant)	6370.35	6374.00	3.64	5880.56	4832.65	7419.67	5881.73	4834.59	7424.81	3.16	1.24	5.61
ICER per additional QALY (£)			3658.58							4217.09	1235.06	8220.71
ICER per additional quitter (£)			105.22							121.41	34.63	233.44
Cost-offset analysis												
Cost savings ratio for maternal health-care only (£)			−0.61							−0.50	−0.88	−0.22
Cost savings ratio for offspring health-care only (£)			0.42							0.36	−0.19	1.19
Cost savings ratio for combined health-care only (£)			−1.20							−1.01	−1.83	−0.42

ESIP = Economics of Smoking in Pregnancy; QALY = quality-adjusted life year; ICER = incremental cost-effectiveness ratio.

women less likely to quit smoking is 3.45%. While this assumption might be made in instances where new interventions are delivered in addition to usual care, it can be relaxed for instances where the new intervention is a direct replacement for usual care, thus ESIP can perform those types of analyses.

The model is restricted to singleton pregnancies. Multiple gestations are infrequent: in 2013 fewer than 2% of all births in England and Wales were multiple births [87]; however, pregnancy outcomes in multiple pregnancies are worse than after singleton ones and so health-care costs are likely to be higher. ESIP would need substantial amendments to account for multiple births; it is not entirely clear how estimates may be affected by excluding the possibility of multiple births but, as these are reasonably rare, any impact is unlikely to be large.

The MiQuit RCT recruited women at an average at 15 weeks gestation and so may have had a limited impact on fetal loss due to miscarriages, which occur principally early in pregnancy; however, we included this outcome in our example, as late miscarriage could be affected by the MiQuit intervention. This may have resulted in some over-estimation of MiQuit's cost-effectiveness in our 'worked example', but a positive feature of ESIP is flexibility and it is possible to re-run analyses removing miscarriage from the list of outcomes as a sensitivity analysis, if desired.

### Application and implication for policy

The ability of ESIP to provide 'common currency' outputs (e.g. cost per QALY) is likely to be of most interest to decision-makers and researchers, as these will allow simple comparisons between cessation interventions delivered in pregnancy and other health-care interventions. Provided the additional costs of delivering an intervention and the likely (or demonstrated) absolute effect on cessation are known, these can be fed into the programmable interface of ESIP to generate life-time estimates for intervention cost-effectiveness without the need for an additional economic model to be built. ESIP inputs currently apply only to the UK population, and so caution is needed when applying ESIP estimates to countries with very different prevalence of smoking behaviours or of smoking-related illnesses. Model outputs may not be generalizable to such jurisdictions; however, with support, it would be straightforward to re-parameterize ESIP with other countries' morbidity and mortality data. ESIP is to be published at: <https://www.nottingham.ac.uk/research/groups/tobaccoandalcohol/smoking-in-pregnancy/esip/index.aspx> and the lead author would be able to provide such support.

One consideration with regard to the cost-effectiveness estimates from the ESIP outputs is to what extent infant outcomes are valued in comparison with maternal outcomes. Currently, there is a lack of international

standardization with regard to the inclusion of infant outcomes not only in evaluations of smoking cessation interventions, but also many other pregnancy-related interventions [88]. In the United Kingdom, current guidance on economic evaluations for decision-making is ambiguous [18]. Many previous evaluations of within-pregnancy smoking cessation interventions have either focused solely on outcomes related to the mother or infant [13]; however, several recent interventions have presented a combined measure [17,24], and thus we presented combined measures of cost-effectiveness to aid comparison with previous evaluations. It is anticipated that guidance regarding the inclusion of infant outcomes is likely to change, although what this societal decision will be cannot be foreseen. The authors hope that we have demonstrated the flexibility of ESIP in terms of valuing both maternal and infant outcomes, allowing decision-makers the facility of having the maximum amount of information available to make an informed decision, irrespective of their viewpoint regarding the valuing of infant outcomes.

### CONCLUSION

ESIP resulted from a systematic approach to address the limitations of previous economic evaluations of smoking cessation interventions used in pregnancy, and offers researchers a comprehensive approach to estimating costs, outcomes and cost-effectiveness. The inclusion of future cost savings for both mother and child enables decision-makers to allocate scarce resources with an information set which demonstrates the longer-term paybacks associated with current investment. Short-term cost-effectiveness ratios are misleading when evaluating preventive interventions because future savings are not included, the result being a suboptimal allocation of resources.

### Declaration of interests

None.

### Acknowledgements

This study was conducted as part of a programme funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research programme (RP-PG-0109-10020). The views expressed in this paper are those of the authors and do not necessarily represent those of the NHS, the NIHR or the Department of Health. TC is a National Institute for Health Research (NIHR) Senior Investigator. T.C., S.L., S.P. and M.J. are members of the UK Centre for Tobacco and Alcohol Studies which receives core funding from the British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research Council, and the Department

of Health under the auspices of the UK Clinical Research Collaboration. T.C. acknowledges support from the East Midlands CLAHRC and is a member of the NIHR School for Primary Care Research. We wish to thank Dr Felix Naughton and the MiQuit study team for allowing us access to and use of the MiQuit study data. We wish to thank Dr Katharine Bowler for her advice on prenatal healthcare and delivery costs.

## References

- Godfrey C., Pickett K., Parrott S., Mdege N., Eapen D. *Estimating the Costs to the NHS of Smoking in Pregnancy for Pregnant Women and Infants*. York: Public Health Research Consortium, University of York; 2010.
- Mason J., Wheeler W., Brown M. J. The economic burden of exposure to secondhand smoke for child and adult never smokers residing in U.S. public housing. *Public Health Rep* 2015; **130**: 230–44.
- Palma S., Pérez-Iglesias R., Pardo-Crespo R., Llorca J., Mariscal M., Delgado-Rodríguez M. Smoking among pregnant women in Cantabria (Spain): trend and determinants of smoking cessation. *BMC Public Health* 2007; **7**: 65.
- Cui Y., Shooshtari S., Forget E. L., Clara I., Cheung K. F. Smoking during pregnancy: findings from the 2009–2010 Canadian community health survey. *PLoS One* 2014; **9**: e84640.
- NHS Information Centre and IFF Research. Infant Feeding Survey 2010: Early Results. The Health and Social Care Information Centre. London: The NHS Information Centre; 2011.
- Tong V. T., Dietz P. M., Farr S. L., D'Angelo D. V., England L. J. Estimates of smoking before and during pregnancy, and smoking cessation during pregnancy: comparing two population-based data sources. *Public Health Rep* 2013; **128**: 179–88.
- Schneider S., Maul H., Freerksen N., Pötschke-Langer M. Who smokes during pregnancy? An analysis of the German perinatal quality survey 2005. *Public Health* 2008; **122**: 1210–6.
- Hilder L., Zhichao Z., Parker M., Jahan S., Chambers G. M. *Australia's Mothers and Babies 2012*. Canberra, The Australian Institute of Health and Welfare; 2014.
- DiFranza J. R., Lew R. A. Effect of maternal cigarette smoking on pregnancy complications and sudden infant death syndrome. *J Fam Pract* 1995; **40**: 385–94.
- Castles A., Adams E. K., Melvin C. L., Kelsch C., Boulton M. L. Effects of smoking during pregnancy. Five meta-analyses. *Am J Prev Med* 1999; **16**: 208–15.
- Shah N. R., Bracken M. B. A systematic review and meta-analysis of prospective studies on the association between maternal cigarette smoking and preterm delivery. *Am J Obstet Gynecol* 2000; **182**: 465–72.
- Jauniaux E., Greenough A. Short and long term outcomes of smoking during pregnancy. *Early Hum Dev* 2007; **83**: 697–8.
- Jones M., Lewis S., Parrott S., Coleman T. Systematic critical review of previous economic evaluations of smoking cessation during pregnancy. *BMJ Open* 2015; **5**: e008998.
- Boyd K. A., Briggs A. H., Bauld L., Sinclair L., Tappin D. Are financial incentives cost-effective to support smoking cessation during pregnancy? *Addiction* 2016; **111**: –370.
- Dornelas E. A., Magnavita J., Beazoglou T., Fischer E. H., Oncken C., Lando H. *et al.* Efficacy and cost-effectiveness of a clinic-based counseling intervention tested in an ethnically diverse sample of pregnant smokers. *Patient Educ Couns* 2006; **64**: 342–9.
- Hueston W. J., Mainous A. G. III, Farrell J. B. A cost-benefit analysis of smoking cessation programs during the first trimester of pregnancy for the prevention of low birthweight. *J Fam Pract* 1994; **39**: 353–7.
- Taylor M. Economic Analysis of Interventions for Smoking Cessation Aimed at Pregnant Women. NICE Guidance PH26, Supplementary Report, National Institute for Health and Care Excellence. Editor. York: York Health Economics Consortium; 2009.
- National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. 2013 04/05/2013. Available at: <http://publications.nice.org.uk/guide-to-the-methods-of-technology-appraisal-2013-pmg9/the-reference-case> (accessed 15 May 2014).
- Leonardi-Bee J., Jere M. L., Britton J. Exposure to parental and sibling smoking and the risk of smoking uptake in childhood and adolescence: a systematic review and meta-analysis. *Thorax* 2011; **66**: 847–55.
- Jones M. J. The development of the Economic impacts of Smoking In Pregnancy (ESIP) model for measuring the impacts of smoking and smoking cessation during pregnancy. Nottingham: School of Medicine, University of Nottingham; 2015, p. 496.
- Newacheck P. W., Taylor W. R. Childhood chronic illness: prevalence, severity, and impact. *Am J Public Health* 1992; **82**: 364–71.
- Lifestyle Statistics and Health and Social Care Information Centre. *Statistics of Smoking: England 2013*. London: Lifestyle Statistics and Health and Social Care Information Centre; 2013.
- Flack S., Taylor M., Trueman P. *Cost-Effectiveness of Interventions for Smoking Cessation, Final Report*. National Institute for Health and Care Excellence. York: York Health Economics Consortium; 2007.
- Mallinder J., Bertranou E., Bacelar M., Roberts S. In: National Institute for Health and Care Excellence, editor. *Economic Analysis of Smoking Cessation in Secondary Care: NICE Public Health Guidance PH48*. London: Matrix Knowledge; 2013.
- Willett W. C., Green A., Stampfer M. J., Speizer F. E., Colditz G. A., Rosner B. *et al.* Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. *N Engl J Med* 1987; **317**: 1303–9.
- Doll R., Peto R., Wheatley K., Gray R., Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. *BMJ* 1994; **309**: 901–11.
- Wolf P. A., D'Agostino R. B., Kannel W. B., Bonita R., Belanger A. J. Cigarette smoking as a risk factor for stroke: the Framingham study. *JAMA* 1988; **259**: 1025–9.
- Jones M., Lewis S., Parrott S., Wormall S., Coleman T. Restarting smoking in the postpartum period after receiving a smoking cessation intervention: a systematic review. *Addiction* 2016; **111**: 981–90.
- McAndrew E., Thompson J., Fellows L., Large A., Speed M., Renfrew M. J. In: The NHS Information Centre for Health and Social Care, editor. *Infant Feeding Survey 2010*. London: Health and Social Care Information Centre; 2012.
- Yudkin P., Hey K., Roberts S., Welch S., Murphy M., Walton R. Abstinence from smoking eight years after participation in randomised controlled trial of nicotine patch. *BMJ* 2003; **327**: 28–9.



31. Information Centre for Health and Social Care and Department of Health. *Health Survey for England*. London: UK Data Service; 2017.
32. Health and Social Care Information Centre. *Hospital Episode Statistics: NHS Maternity Statistics—England*. London: Health and Social Care Information Centre; 2015.
33. Office for National Statistics. *Gestation-specific infant mortality in England and Wales*. 2015. 15th October 2014. Available at: <http://www.ons.gov.uk/ons/rel/child-health/gestation-specific-infant-mortality-in-england-and-wales/index.html> (accessed 15 September 2015).
34. Office for National Statistics. *Child mortality statistics: Childhood, infant and perinatal*. 2015. 10th March 2015. Available at: <http://www.ons.gov.uk/ons/rel/vsob1/child-mortality-statistics-childhood-infant-and-perinatal/index.html> (accessed 17 September 2015).
35. Flowers J., Hill E., Tennison I., Tovey R. Chronic disease prevalence by age, sex and region in 2008, Eastern Region Public Health Observatory (ERPHO). London: Public Health England; 2010.
36. Townsend N., Wickramasinghe K., Bhatnagar P., Smolina K., Nichols M., Leal J. et al. *Coronary Heart Disease Statistics: A Compendium of Health Statistics: 2012 edition*. London: Department of Public Health, University of Oxford; 2012.
37. Forman D., Stockton D., Møller H., Quinn M., Babb P., de Angelis R. et al. Cancer prevalence in the UK: results from the EUROPREVAL study. *Ann Oncol* 2003; **14**: 648–54.
38. US Department of Health and Human Services (USDHHS). *The Health Consequences of Smoking—50 Years of Progress. A Report of the Surgeon General, Department of Health and Human Services*. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
39. Royal College of Physicians (RCP). *Passive Smoking and Children. A report by the Tobacco Advisory Group*. London: RCP; 2010.
40. Mu M., Ye S., Bai M. J., Liu G. L., Tong Y., Wang S. F. et al. Birth weight and subsequent risk of asthma: a systematic review and meta-analysis. *Heart Lung Circ* 2014; **6**: 511–9.
41. Burke H., Leonardi-Bee J., Hashim A., Pine-Abata H., Chen Y., Cook D. G. et al. Prenatal and passive smoke exposure and incidence of asthma and wheeze: systematic review and meta-analysis. *Pediatrics* 2012; **129**: 735–44.
42. Office for National Statistics. *Mortality Statistics: Death Registered in England and Wales (Series DR)*. London: Office for National Statistics; 2015.
43. Office for National Statistics. *Mortality Statistics: Cause, England and Wales (Series DH2)*. London: Office for National Statistics; 2004–2005.
44. Office for National Statistics. *Historic and Projected Mortality Data from the Period and Cohort Life Tables, 2012-based, UK, 1981–2062*. London: Office for National Statistics; 2013.
45. Doll R., Peto R., Boreham J., Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. *BMJ* 2004; **328**: 1519.
46. Office for National Statistics. *Compendium: Adult Smoking Habits in Great Britain, 2013*. London: Office for National Statistics; 2014.
47. Li C. I., Daling J. R., Emanuel I. Birthweight and risk of overall and cause-specific childhood mortality. *Paediatr Perinat Epidemiol* 2003; **17**: 164–70.
48. Maheswaran H., Petrou S., Rees K., Stranges S. Estimating EQ-5D utility values for major health behavioural risk factors in England. *J Epidemiol Community Health* 2013; **67**: 172–80.
49. National Collaborating Centre for Women's and Children's Health (UK). *Appendix H, Cost effectiveness of aspirin compared with no aspirin in preventing pre-eclampsia in women at risk of developing pre-eclampsia*, in *Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy*. London: RCOG Press; 2010.
50. Partridge J. C., Sendowski M. D., Martinez A. M., Caughey A. B. Resuscitation of likely nonviable infants: a cost-utility analysis after the Born-Alive Infant Protection Act. *Am J Obstet Gynecol* 2012; **206**: 49.e1–0.
51. Gillespie P., O'Neill C., Adams E., Turner K., O'Donovan D., Brugha R. et al. The cost and cost-effectiveness of opportunistic screening for chlamydia trachomatis in Ireland. *Sex Transm Infect* 2012; **88**: 222–8.
52. The Community Pharmacy Medicines Management Project Evaluation Team The MEDMAN study: a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. *Fam Pract* 2007; **24**: 189–200.
53. Starkie H. J., Briggs A. H., Chambers M. G., Jones P. Predicting EQ-5D values using the SGRQ. *Value Health* 2011; **14**: 354–60.
54. Pickard A. S., Neary M. P., Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. *Health Qual Life Outcomes* 2007; **5**: 70.
55. Haacke C., Althaus A., Spottke A., Siebert U., Back T., Dodel R. Long-term outcome after stroke: evaluating health-related quality of life using utility measurements. *Stroke* 2006; **37**: 193–8.
56. Carroll A. E., Downs S. M. Improving decision analyses: parent preferences (utility values) for pediatric health outcomes. *J Pediatr* 2009; **155**: 21–5, 25.e1–5.
57. Department of Health. *NHS Reference Costs: Financial year 2014–15*. London: Department of Health; 2015.
58. Department of Health. *NHS reference costs*. 2015. Available at: <https://www.gov.uk/government/collections/nhs-reference-costs> (accessed 19 May 2015).
59. Imperial College London. *Neonatal Data Analysis Unit (NDAU): NDAU Report 2015*. 2016. Available at: <https://www1.imperial.ac.uk/neonataldataanalysis/supporting/na/> (accessed 15 November 2016).
60. European Lung White Book. *Respiratory health and disease in Europe 2014*. Available at: <http://www.erswhitebook.org/> (accessed 8 September 2014).
61. Liu J. L., Maniadakis N., Gray A., Rayner M. The economic burden of coronary heart disease in the UK. *Heart* 2002; **88**: 597–603.
62. Youman P., Wilson K., Harraf F., Kalra L. The economic burden of stroke in the United Kingdom. *Pharmacoeconomics* 2003; **21**: 43–50.
63. Curtis L., Burns A. *Unit Costs of Health and Social Care 2016*. Canterbury: University of Kent; 2016.
64. Briggs A., Claxton K., Sculpher M. Decision Modelling for Health Economic Evaluation. In: *Handbooks in Health Economic Evaluation*. Oxford: Oxford University Press; 2006.
65. Doubilet P., Begg C. B., Weinstein M. C., Braun P., McNeil B. J. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. *Med Decis Making* 1985; **5**: 157–77.
66. Microsoft Excel 2010. Microsoft Office Professional Plus. Redmond, WA: Microsoft Corporation; 2010.



67. Cooper S., Foster K., Naughton E., Leonardi-Bee J., Sutton S., Ussher M. *et al.* Pilot study to evaluate a tailored text message intervention for pregnant smokers (MiQuit): study protocol for a randomised controlled trial. *Trials* 2015; **16**: 29.
68. Naughton E., Cooper S., Foster K., Emery J., Leonardi-Bee J., Sutton S. *et al.* Large multi-centre pilot randomized controlled trial testing a low-cost, tailored, self-help smoking cessation text message intervention for pregnant smokers (MiQuit). *Addiction* 2017; **112**: 1238–49.
69. Wilson E. B. Probable inference, the law of succession, and statistical inference. *J Am Stat Assoc* 1927; **22**: 209–12.
70. Miller I., Miller M. *John E. Freund's Mathematical Statistics with Applications*, 7th edn. Upper Saddle River, NJ: Pearson Prentice-Hall; 2004.
71. Cohen D. J., Reynolds M. R. Interpreting the results of cost-effectiveness studies. *J Am Coll Cardiol* 2008; **52**: 2119–26.
72. McCabe C., Claxton K., Culyer A. J. The NICE cost-effectiveness threshold: what it is and what that means. *Pharmacoeconomics* 2008; **26**: 733–44.
73. Marseille E., Larson B., Kazi D. S., Kahn J. G., Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. *Bull World Health Organ* 2015; **93**: 118–24.
74. Marks J. S., Koplan J. P., Hogue C. J. R., Dalmat M. E. A cost-benefit/cost-effectiveness analysis of smoking cessation for pregnant women. *Am J Prev Med* 1990; **6**: 282–9.
75. Ruger J. P., Weinstein M. C., Hammond S. K., Kearney M. H., Emmons K. M. Cost-effectiveness of motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women: a randomized controlled trial. *Value Health* 2008; **11**: 191–8.
76. Cnattingius S. The epidemiology of smoking during pregnancy: smoking prevalence, maternal characteristics, and pregnancy outcomes. *Nicotine Tob Res* 2004; **6**: S125–S140.
77. Munafò M. R., Heron J., Araya R. Smoking patterns during pregnancy and postnatal period and depressive symptoms. *Nicotine Tob Res* 2008; **10**: 1609–20.
78. Eiden R. D., Homish G. G., Colder C. R., Schuetz P., Gray T. R., Huestis M. A. Changes in smoking patterns during pregnancy. *Subst Use Misuse* 2013; **48**: 513–22.
79. Shaw A., Ritchie D., Semple S., Turner S., O'Donnell R., Amos A. *et al.* *Reducing Children's Exposure to Second Hand Smoke in the Home: A literature review*. Scotland: ASH; 2012.
80. Petrou S., Gray A. Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. *BMJ* 2011; **342**: d1766.
81. Caponnetto P., Polosa R. Common predictors of smoking cessation in clinical practice. *Respir Med* 2008; **102**: 1182–92.
82. Vangeli E., Stapleton J., Smit E. S., Borland R., West R. Predictors of attempts to stop smoking and their success in adult general population samples: a systematic review. *Addiction* 2011; **106**: 2110–21.
83. Zhou X., Nonnemaker J., Sherrill B., Gilson A. W., Coste F., West R. Attempts to quit smoking and relapse: factors associated with success or failure from the ATTEMPT cohort study. *Addict Behav* 2009; **34**: 365–73.
84. Zhu S. H., Sun J., Billings S. C., Choi W. S., Malarcher A. Predictors of smoking cessation in U.S. adolescents. *Am J Prev Med* 1999; **16**: 202–7.
85. US Department of Health and Human Services (USDHHS). *Women and Smoking: A report of the Surgeon General*. Washington, DC: USDHHS; 2001.
86. Office for National Statistics (ONS). *Childbearing for Women Born in Different Years, 2013*. 2014; London: ONS.
87. Office for National Statistics (ONS). *Characteristics of Birth 2, England and Wales—2013. Characteristics of Birth 2, England and Wales*. London: ONS; 2014.
88. Goldhaber-Fiebert J. D., Brandeau M. L. Evaluating cost-effectiveness of interventions that affect fertility and childbearing: how health effects are measured matters. *Med Decis Making* 2015; **35**: 818–46.

## Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Appendix S1** Technical summary of methods.

**Appendix S2** Transition probabilities used in model.

**Appendix S3** Prevalence of morbidities and mortality.

**Appendix S4** Detailed figures of model structure.

**Appendix S5** ICD-10 codes and NHS reference costs codes.